Michael Pryor, MD
Urology · Spartanburg, SCNPI 1699711317
Payments from drug & device makers
Across 283 payments — averaging $18.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$1K
- Astellas Pharma US Inc$594
- Boston Scientific$592
- AbbVie$549
- Antares Pharma, Inc.$417
- Procept Biorobotics Corporation$264
- plus $1K from 33 others
What the payments were for
- Food & beverage$5,04399%
- Education$551%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 103 | $1,315 |
| Astellas Pharma US Inc | 38 | $594 |
| Boston Scientific | 13 | $592 |
| AbbVie | 32 | $549 |
| Antares Pharma, Inc. | 25 | $417 |
| Procept Biorobotics Corporation | 3 | $264 |
| Cipla USA Inc. | 2 | $168 |
| Pfizer | 8 | $126 |
| Johnson & Johnson | 6 | $105 |
| Merck | 5 | $93 |
| Bayer | 4 | $74 |
| Sumitomo Pharma America, Inc. | 4 | $67 |
| Tolmar Pharmaceuticals, Inc. | 3 | $67 |
| Urovant Sciences Inc | 4 | $61 |
| Olympus America Inc. | 3 | $56 |
| Convatec Inc. | 2 | $55 |
| Medtronic | 2 | $51 |
| Smith+Nephew | 2 | $41 |
| Urogen Pharma, Inc. | 2 | $37 |
| Laborie Medical Technologies Corp. | 2 | $32 |
| Myovant Sciences Inc. | 1 | $30 |
| Baudax Bio Inc. | 2 | $26 |
| Axonics, Inc. | 1 | $22 |
| AstraZeneca | 1 | $22 |
| Baxter Healthcare | 1 | $19 |
| Amgen | 1 | $19 |
| Novartis | 1 | $18 |
| Sanofi | 1 | $18 |
| Dendreon Pharmaceuticals LLC | 1 | $17 |
| Clarus Therapeutics Inc. | 1 | $17 |
| Travere Therapeutics, Inc. | 1 | $16 |
| Metuchen Pharmaceuticals | 1 | $16 |
| Ferring Pharmaceuticals Inc. | 1 | $15 |
| Aytu Biopharma, Inc. | 1 | $15 |
| Tolmar, Inc. | 1 | $14 |
| Angiodynamics, Inc. | 1 | $14 |
| Blue Earth Diagnostics | 1 | $14 |
| Endo Pharmaceuticals Inc. | 1 | $12 |
| Ambu Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,098 in reported general payments places this provider in the 60th percentile of 196 urology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 75 | $47,874 |
| MyrbetriqMirabegron | 54 | $35,629 |
| XyostedTestosterone Enanthate | 32 | $18,942 |
| Tamsulosin Hcl | 572 | $8,852 |
| Testosterone | 52 | $8,409 |
| Testosterone Cypionate | 266 | $5,822 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 193 | $3,938 |
| Finasteride | 318 | $3,759 |
| Potassium Citrate ErPotassium Citrate | 20 | $2,588 |
| Tadalafil | 87 | $2,493 |
| Dutasteride | 43 | $2,262 |
| ClomidClomiphene Citrate | 14 | $2,236 |
| Silodosin | 26 | $1,682 |
| Oxybutynin Chloride ErOxybutynin Chloride | 43 | $646 |
| Cefdinir | 40 | $643 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $67 | $47,87475 claims |
| Astellas Pharma US IncMyrbetriq | $594 | $35,62954 claims |
| Antares Pharma, Inc.Xyosted | $417 | $18,94232 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 196 urology providers in South Carolina.
Other urology in Spartanburg
- Erin AndersonSpartanburg$9K
- Eric CoronatoSpartanburg$7K
- Robert BritaniskySpartanburg$7K
- Robert StrehlowSpartanburg$7K
- Neal ShoreMyrtle Beach$63.3M
- Sandip PrasadCharleston$2.4M
- Stephen SavageCharleston$2.1M
- Justin EllettN Charleston$727K
- Thomas KeaneCharleston$281K
- Kimberly BurgessGreenville$271K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.